Leerink Partnrs Has Positive Estimate for DexCom Q4 Earnings

DexCom, Inc. (NASDAQ:DXCM) – Stock analysts at Leerink Partnrs raised their Q4 2024 earnings per share (EPS) estimates for DexCom in a report issued on Monday, November 25th. Leerink Partnrs analyst M. Kratky now anticipates that the medical device company will post earnings of $0.49 per share for the quarter, up from their prior forecast of $0.48. The consensus estimate for DexCom’s current full-year earnings is $1.71 per share. Leerink Partnrs also issued estimates for DexCom’s FY2026 earnings at $2.43 EPS, FY2027 earnings at $2.72 EPS and FY2028 earnings at $3.06 EPS.

DXCM has been the subject of a number of other research reports. Sanford C. Bernstein boosted their price target on DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. Piper Sandler reissued an “overweight” rating and set a $90.00 price objective on shares of DexCom in a research report on Monday, August 26th. StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. JPMorgan Chase & Co. boosted their price objective on DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Finally, Wells Fargo & Company boosted their price objective on DexCom from $80.00 to $90.00 and gave the stock an “overweight” rating in a research report on Friday, October 25th. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, DexCom presently has an average rating of “Moderate Buy” and an average target price of $104.59.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $77.94 on Tuesday. DexCom has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The business has a 50-day moving average of $70.94 and a two-hundred day moving average of $88.58. The stock has a market capitalization of $30.44 billion, a P/E ratio of 46.67, a P/E/G ratio of 2.23 and a beta of 1.17. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12.

Insider Activity at DexCom

In other news, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the sale, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. This represents a 0.56 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. This represents a 0.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 5,431 shares of company stock worth $399,319 over the last three months. Company insiders own 0.30% of the company’s stock.

Institutional Investors Weigh In On DexCom

Several large investors have recently modified their holdings of DXCM. Jennison Associates LLC increased its holdings in DexCom by 1,683.2% during the 3rd quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock valued at $464,782,000 after purchasing an additional 6,544,102 shares in the last quarter. Westfield Capital Management Co. LP grew its holdings in shares of DexCom by 44.6% during the third quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock worth $190,532,000 after purchasing an additional 876,739 shares during the last quarter. Two Sigma Advisers LP increased its stake in shares of DexCom by 182.7% in the third quarter. Two Sigma Advisers LP now owns 1,143,476 shares of the medical device company’s stock valued at $76,659,000 after buying an additional 739,000 shares in the last quarter. Canada Pension Plan Investment Board raised its holdings in shares of DexCom by 189.1% in the second quarter. Canada Pension Plan Investment Board now owns 665,646 shares of the medical device company’s stock valued at $75,471,000 after buying an additional 435,401 shares during the last quarter. Finally, Intech Investment Management LLC lifted its position in DexCom by 2,083.0% during the 3rd quarter. Intech Investment Management LLC now owns 387,330 shares of the medical device company’s stock worth $25,967,000 after buying an additional 369,587 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.